Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
AJOB Neurosci ; 15(2): 82-89, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-38315212

RESUMO

The psychedelic psilocybin has shown promise both as treatment for psychiatric conditions and as a means of improving well-being in healthy individuals. In some jurisdictions (e.g., Oregon, USA), psilocybin use for both purposes is or will soon be allowed and yet, public attitudes toward this shift are understudied. We asked a nationally representative sample of 795 US Americans to evaluate the moral status of psilocybin use in an appropriately licensed setting for either treatment of a psychiatric condition or well-being enhancement. Showing strong bipartisan support, participants rated the individual's decision as morally positive in both contexts. These results can inform effective policy-making decisions around supervised psilocybin use, given robust public attitudes as elicited in the context of an innovative regulatory model. We did not explore attitudes to psilocybin use in unsupervised or non-licensed community or social settings.


Assuntos
Alucinógenos , Transtornos Mentais , Humanos , Psilocibina/uso terapêutico , Alucinógenos/uso terapêutico , Tomada de Decisões , Política Pública
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...